Artelo Biosciences Inc. (NASDAQ: ARTL), a San Diego, California, and Dublin, Ireland-based clinical-stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system, announced on Monday it received a Clinical Trial Authorization (CTA) in the U.K. for its Cancer Appetite Recovery Study (CAReS).
The study will look into ART27.13, a highly potent, peripherally restricted synthetic, dual G protein-coupled receptor agonist believed to target peripheral CB1/CB2 receptors in the endocannabinoid system, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca plc (NASDAQ: AZN), ART27.13 has been in five Phase 1 clinical studies including over 200 subjects, where it demonstrated a statistically significant and dose-dependent increase in body weight in healthy subjects.
Understanding Trials In The U.K.
Before a clinical …